Is Dr. Paul Cox listed as an investigator or sponsor on FDA IND applications for Neurocept?

1. What the sources say about Cox and FDA interactions

Multiple profiles and press pieces state Dr. Cox presented animal data to the U.S. Food and Drug Administration and “set up clinical trials” or “sought approval” to test L‑serine in humans; Brain Chemistry Labs’ own news copy says “We have proven in an FDA‑approved Phase I clinical trial that L‑serine is safe” and that Cox has been involved in trials with collaborators ^{[1] [2] [3]}. Fortune and other longform coverage describe Cox’s pivot to L‑serine and his efforts to advance clinical research ^[4]. These accounts portray regulatory engagement but do not reproduce IND documents or name roles on those filings ^{[4] [1] [3]}.

2. What the sources do not show: no mention of Neurocept as an IND or sponsor

None of the supplied results mention a company or product called Neurocept, nor do they reproduce or cite FDA IND filings that name Cox as sponsor or named investigator on an IND for Neurocept. The available material centers on L‑serine trials conducted or publicized by Brain Chemistry Labs/The Institute for EthnoMedicine and collaborations ^{[3] [1]}. Therefore, claims that Cox is listed on an IND for “Neurocept” are unsupported by these sources (available sources do not mention Neurocept).

3. Where sources identify trials and partners, and what that implies

One source notes a Phase II trial of L‑serine for mild cognitive impairment in collaboration with Houston Methodist Research Institute and states an FDA‑approved Phase I occurred ^{[5] [3]}. Those descriptions imply Cox worked with institutional partners on registered clinical research; they do not, however, provide IND paperwork or identify who legally sponsored the IND (an investigator can differ from the IND sponsor, and institutional partnerships often assign sponsorship to a hospital, university, or company) ^{[5] [3]}. The reporting therefore supports involvement in trials but not legal attribution on FDA forms.

4. Competing interpretations in the reporting

Journalistic profiles (Fortune) and Brain Chemistry Labs’ publicity portray Cox as the driving scientific force behind L‑serine trials and stress his role in shepherding work to the FDA ^{[4] [3]}. Largely promotional outlets reiterate the narrative that Cox “took the data to the FDA” and “set up clinical trials” ^{[1] [2] [6]}. Those accounts reflect Cox’s agenda to advance L‑serine and his organization; they do not substitute for primary regulatory documents that would definitively list sponsor/investigator names on INDs ^{[1] [2] [3]}.

5. What would be needed to answer definitively

To state definitively whether Dr. Cox is listed as an investigator or sponsor on an FDA IND for Neurocept or any specific IND, one must consult primary regulatory records: the FDA’s public IND database entries, clinicaltrials.gov trial records (which list sponsors and Principal Investigators), or copies of the IND submission and FDA correspondence. The provided sources do not include those records or clinicaltrials.gov entries for Neurocept (available sources do not mention Neurocept; available sources do not include IND paperwork).

6. Bottom line and suggested next steps

Based on the available reporting, Dr. Paul Cox has been publicly linked to L‑serine research and to initiating FDA‑regulated human trials ^{[1] [3]}. The supplied materials do not show him named on an IND as sponsor or investigator for a product called Neurocept and do not provide IND documents to verify such a claim (available sources do not mention Neurocept; available sources do not include IND forms). To resolve this question authoritatively, check FDA and clinicaltrials.gov records for any IND or registered trial named Neurocept and review sponsor/investigator fields, or request the specific IND number and examine the filing.